CG Oncology (CGON) Return on Sales (2023 - 2026)

CG Oncology (CGON) has 4 years of Return on Sales data on file, last reported at 0.55% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 607.0% year-over-year to 0.55%; the trailing twelve-month figure through Mar 2026 stood at 0.37% (up 123.0% YoY), and the FY2025 full-year result was 0.4%, up 37.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.55%, down from 0.18% in the prior quarter.
• Across five years, Return on Sales topped out at 0.18% in Q4 2025 and bottomed at 165.51% in Q4 2023.
• The 4-year median for Return on Sales is 1.2% (2024), against an average of 16.37%.
• The widest annual swing landed in 2024, when Return on Sales soared 16481 bps; it then sank 631 bps in 2025.
• A 4-year view of Return on Sales shows it stood at 165.51% in 2023, then jumped by 100 bps to 0.7% in 2024, then jumped by 75 bps to 0.18% in 2025, then sank by 212 bps to 0.55% in 2026.
• The last three Return on Sales figures came in at 0.55% (Q1 2026), 0.18% (Q4 2025), and 0.26% (Q3 2025), per Business Quant data.

Peer Comparison